XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 30 filers reported holding XILIO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RiverVest Venture Management LLC | 1,441,444 | $3,041,447 | 7.52% |
| Trustees of Columbia University in the City of New York | 249,635 | $526,730 | 0.97% |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $5,822,216 | 0.90% |
| Octagon Capital Advisors LP | 2,318,500 | $4,892,035 | 0.75% |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $5,919,421 | 0.66% |
| HARVARD MANAGEMENT CO INC | 416,059 | $878 | 0.10% |
| Rock Springs Capital Management LP | 1,440,759 | $3,040,001 | 0.08% |
| Soleus Capital Management, L.P. | 226,941 | $478,846 | 0.04% |
| Artal Group S.A. | 450,000 | $950 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 110,481 | $233,115 | 0.01% |